[HTML][HTML] Biological challenges of BRAF inhibitor therapy
I Puzanov, P Burnett, KT Flaherty - Molecular Oncology, 2011 - Elsevier
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
Biological challenges of BRAF inhibitor therapy.
I Puzanov, P Burnett, KT Flaherty - Molecular Oncology, 2011 - europepmc.org
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
Biological challenges of BRAF inhibitor therapy
I Puzanov, P Burnett, KT Flaherty - Molecular Oncology, 2011 - Wiley Online Library
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
Biological challenges of BRAF inhibitor therapy
I Puzanov, P Burnett, KT Flaherty - Molecular Oncology, 2011 - search.ebscohost.com
Abstract: Activating mutations in BRAF, a constituent of the map kinase pathway, were first
discovered as being most prevalent in melanoma in 2002. Only recently have potent and …
discovered as being most prevalent in melanoma in 2002. Only recently have potent and …
Biological challenges of BRAF inhibitor therapy
I Puzanov, P Burnett, KT Flaherty - Molecular Oncology, 2011 - infona.pl
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
Biological challenges of BRAF inhibitor therapy
I Puzanov, P Burnett, KT Flaherty - Molecular Oncology, 2011 - search.proquest.com
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
Biological challenges of BRAF inhibitor therapy
I Puzanov, P Burnett, KT Flaherty - Molecular oncology, 2011 - pubmed.ncbi.nlm.nih.gov
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
[HTML][HTML] Biological challenges of BRAF inhibitor therapy
I Puzanov, P Burnett, KT Flaherty - Molecular Oncology, 2011 - ncbi.nlm.nih.gov
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
as being most prevalent in melanoma in 2002. Only recently have potent and selective …